晚期前列腺癌患者的管理:2017年晚期前列腺癌共识会议APCCC报告
2017年晚期前列腺癌共识会议(APCCC)由60位国际专家针对10个争议领域制定150个预设问题,采用改良Delphi流程匿名投票。投票结果基于专家意见而非系统文献综述或Meta分析,可用于缺乏高级别证据的晚期前列腺癌管理决策支持,但个体化治疗需结合全部可用数据。
要点
- 60位国际专家对150个预设问题匿名投票,覆盖10个晚期前列腺癌争议领域。
- 投票基于专家意见,非标准文献综述或Meta分析,支持程度不一。
- 结果可用于缺乏高级别证据时的决策支持,但需个体化并强调临床试验入组。
核心结论
- 专家投票结果可用于晚期前列腺癌缺乏高级别证据领域的管理支持,但个体化治疗决策应始终基于全部可用数据。
- 应强烈鼓励晚期前列腺癌患者参加临床试验。
- APCCC 2017再次识别出需要专门设计试验来解决的重要领域。
研究设计与样本
- APCCC 2017为共识会议,由60位国际前列腺癌专家组成专家组制定议程和共识问题。
- 识别了10个晚期前列腺癌管理争议领域,包括高危局限性和局部晚期前列腺癌、「寡转移」前列腺癌、去势初治和去势抵抗性前列腺癌、影像学在晚期前列腺癌中的作用、破骨细胞靶向治疗、血液和组织分子特征、遗传咨询/检测、全身治疗副作用、前列腺癌药物全球可及性。
- 专家组对150个预设问题公开但匿名投票,问题按改良Delphi流程制定。
主要发现
- 投票基于专家组成员的意见,而非基于标准文献综述或Meta分析。
- 投票结果的支持程度不一,反映在本文措辞及补充数据记录的详细投票结果中。
临床怎么用
- 专家投票结果可用于晚期前列腺癌管理缺乏高级别证据领域的支持。
- 个体化治疗决策应始终基于全部可用数据,包括疾病范围和位置、既往治疗类型、宿主因素(含合并症)、患者偏好、当前和新兴证据以及后勤和经济限制。
- 应强烈鼓励晚期前列腺癌患者参加临床试验。
局限性
- 投票基于专家组成员意见,而非基于标准文献综述或Meta分析。
- 投票结果的支持程度不一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. The Advanced Prostate Cancer Consensus Conference (APCCC) 2017 addressed some of these topics. OBJECTIVE: To present the report of APCCC 2017. DESIGN, SETTING, AND PARTICIPANTS: Ten important areas of controversy in APC management were identified: high-risk localised and locally advanced prostate cancer; "oligometastatic" prostate cancer; castration-naïve and castration-resistant prostate cancer; the role of imaging in APC; osteoclast-targeted therapy; molecular characterisation of blood and tissue; genetic counselling/testing; side effects of systemic treatment(s); global access to prostate cancer drugs. A panel of 60 international prostate cancer experts developed the program and the consensus questions. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The panel voted publicly but anonymously on 150 predefined questions, which have been developed following a modified Delphi process. RESULTS AND LIMITATIONS: Voting is based on panellist opinion, and thus is not based on a standard literature review or meta-analysis. The outcomes of the voting had varying degrees of support, as reflected in the wording of this article, as well as in the detailed voting results recorded in Supplementary data. CONCLUSIONS: The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available, including disease extent and location, prior therapies regardless of type, host factors including comorbidities, as well as patient preferences, current and emerging evidence, and logistical and economic constraints. Inclusion of men with APC in clinical trials should be strongly encouraged. Importantly, APCCC 2017 again identified important areas in need of trials specifically designed to address them. PATIENT SUMMARY: The second Advanced Prostate Cancer Consensus Conference APCCC 2017 did provide a forum for discussion and debates on current treatment options for men with advanced prostate cancer. The aim of the conference is to bring the expertise of world experts to care givers around the world who see less patients with prostate cancer. The conference concluded with a discussion and voting of the expert panel on predefined consensus questions, targeting areas of primary clinical relevance. The results of these expert opinion votes are embedded in the clinical context of current treatment of men with advanced prostate cancer and provide a practical guide to clinicians to assist in the discussions with men with prostate cancer as part of a shared and multidisciplinary decision-making process.
引用
- Gillessen S, Attard G, Beer TM, et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2017. PMID: 28655541. doi:10.1016/j.eururo.2017.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。